Analyst consensus rating
Karyopharm Therapeutics Analyst Rating: Buy
Direct answer
Karyopharm Therapeutics's consensus rating is Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.25.
Forecast evidence checked September 7, 2026.
Get free Karyopharm Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.79
- Average price target
- $7.25
- High price target
- $11.00
- Low price target
- $3.00
- Low target gap
- +67.6%
- Target upside
- +305%
- High target gap
- +514.5%
- Target range width
- 446.9%
- Consensus rating
- Buy
- Analysts
- 4
- Evidence date
- September 7, 2026
- Valid through
- September 14, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Karyopharm Therapeutics?
Karyopharm Therapeutics has a verified Buy consensus. The same dataset has an average price target of $7.25.
How far are Karyopharm Therapeutics's low and high targets from the recorded price?
The low target implies +67.6%, while the high target implies +514.5%.
How many analysts are included in Karyopharm Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Karyopharm Therapeutics's target upside or downside calculated?
The average target of $7.25 is divided by the recorded price of $1.79, then one is subtracted to produce +305%. This does not guarantee a future return.
When was Karyopharm Therapeutics's analyst forecast verified?
The data was verified on 2026-09-07. The dataset is valid through 2026-09-14.